Kintor Reaffirms Drug R&D Focus as Cosmetics Remain Ancillary Revenue Stream

Kintor Pharmaceutical Ltd ( (HK:9939) ) has shared an update.

Kintor Pharmaceutical has clarified that its anti-hair loss foam, containing lead asset KX-826 as the main ingredient, is part of its KOSHINÉ cosmetic line and remains ancillary to its primary drug development and commercialization activities. The company emphasized that the previously disclosed RMB100 million sales target for the cosmetic product is a long-term cumulative goal, and that sales from the cosmetics business will primarily support its medical and biological R&D.

Management detailed that a majority of the group’s 121 staff are focused on drug R&D, supply and GMP production, and that R&D expenses are expected to exceed half of total costs in 2025, driven by Phase II and III trials for KX-826 in male androgenetic alopecia and Phase II trials of GT20029 for acne in China. The board also signaled confidence in the company’s liquidity, citing ongoing negotiations for bank facilities and equity financing, and affirmed that its strategic focus will remain on its listing business and commercialization preparations for core products.

The most recent analyst rating on (HK:9939) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.

More about Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Limited is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong that focuses on the development and commercialization of innovative therapies. Its core pipeline centers on KX-826 for androgenetic alopecia and GT20029 for acne vulgaris, alongside other drug candidates, while it also operates a smaller ancillary cosmetics business under the KOSHINÉ brand.

Average Trading Volume: 2,229,970

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.32B

For a thorough assessment of 9939 stock, go to TipRanks’ Stock Analysis page.